miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma

Oncotarget

Volumn 6, Issue 36, 2015, Pages 39225-39234

  Yu, Lei ^a   Gong, Xuejun ^b   Sun, Lei ^a   Yao, Hong ^a   Lu, Baoling ^a   Zhu, Liying ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CHD5; Hepatocellular carcinoma; microRNA; miR 454

Indexed keywords

DNA BINDING PROTEIN; MICRORNA; MICRORNA 454; PROTEIN CHD5; UNCLASSIFIED DRUG; CHD5 PROTEIN, HUMAN; DNA HELICASE; MIRN454 MICRORNA, HUMAN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA HELICASES; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; NERVE TISSUE PROTEINS; ONCOGENES;

EID: 84948768211     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4407     Document Type: Article

References (48)

1. He X, Li J, Guo W, Liu W, Yu J, Song W, Dong L, Wang F, Yu S, Zheng Y, Chen S, Kong Y and Liu C. Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget. 2015; 6:2302-2314.
2. Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, Cescon M, Chieco P, Bolondi L and Gramantieri L. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget. 2014; 5:10607-10620.
3. Zhou HC, Fang JH, Luo X, Zhang L, Yang J, Zhang C and Zhuang SM. Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells. Oncotarget. 2014; 5:12177-12188.
4. Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee SK, Lee SJ, Kim KM, Park JW and Kim SG. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget. 2014; 5:2792-2806.
5. Lam KL, Yang KL, Sunderasan E and Ong MT. Latex C-serum from Hevea brasiliensis induces non-apoptotic cell death in hepatocellular carcinoma cell line (HepG2). Cell proliferation. 2012; 45:577-585.
6. Wang L, Sun L, Huang J and Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell proliferation. 2011; 44:291-299.
7. Zhang X, Hu S, Wang L, Yan B, Zhao J, Yang A and Zhang R. MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochemical and biophysical research communications. 2014; 443:1078-1084.
8. Gao B, Gao K, Li L, Huang Z and Lin L. miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomedicine&pharmacotherapy = Biomedecine&pharmacotherapie. 2014; 68:143-148.
9. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S and Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PloS one. 2013; 8:e60155.
10. Jung CJ, Iyengar S, Blahnik KR, Ajuha TP, Jiang JX, Farnham PJ and Zern M. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PloS one. 2011; 6:e27740.
11. Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W, Yang YZ, Luo RZ, Zhang CZ and Yun JP. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget. 2014; 5:5113-5124.
12. Fei B and Wu H. MiR-378 Inhibits Progression of Human Gastric Cancer MGC-803 Cells by Targeting MAPK1 In Vitro. Oncology research. 2013; 20:557-564.
13. Li Z, Yu X, Shen J, Chan MT and Wu WK. MicroRNA in intervertebral disc degeneration. Cell proliferation. 2015; 48:278-283.
14. Sidiropoulos KG, White NM, Bui A, Ding Q, Boulos P, Pampalakis G, Khella H, Samuel JN, Sotiropoulou G and Yousef GM. Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience. 2014; 1:709-724.
15. Sanchez-Diaz PC, Hsiao TH, Zou Y, Sugalski AJ, Heim-Hall J, Chen Y, Langevin AM and Hung JY. In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. Oncoscience. 2014; 1:599-608.
16. Gurung B, Katona BW and Hua X. Menin-mediated regulation of miRNA biogenesis uncovers the IRS2 pathway as a target for regulating pancreatic beta cells. Oncoscience. 2014; 1:562-566.
17. Han G, Wang Y and Bi W. C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncology research. 2012; 149-156.
18. Li Z, Yu X, Shen J, Wu WK and Chan MT. MicroRNA expression and its clinical implications in Ewing's sarcoma. Cell proliferation. 2015; 48:1-6.
19. Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X and Qiu G. MicroRNA-10b Promotes Nucleus Pulposus Cell Proliferation through RhoC-Akt Pathway by Targeting HOXD10 in Intervetebral Disc Degeneration. PloS one. 2013; 8:e83080.
20. Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N, Tuvar A, Chuderland D, Stemmer SM, Ben-Aharon I and Shalgi R. MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience. 2014; 1:250-261.
21. Zhou J, Song S, Cen J, Zhu D, Li D and Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncology research. 2012; 20:197-203.
22. Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J and Feng F. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2015; 6:17559-17569.
23. Li Z, Yu X, Shen J and Jiang Y. MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015; 6:4562-4568.
24. Luzhna L and Kovalchuk O. Low dose irradiation profoundly affects transcriptome and microRNAme in rat mammary gland tissues. Oncoscience. 2014; 1:751-762.
25. Xiao X, Tang C, Xiao S, Fu C and Yu P. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncology research. 2013; 20:537-544.
26. Wu W, He X, Kong J and Ye B. Mir-373 affects human lung cancer cells' growth and its E-cadherin expression. Oncology research. 2012; 20:163-170.
27. Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, Liu C, Song W, Wang F, Zhang J, Shen J and Yu J. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015; 18:43-54.
28. Li H, Gupta S, Du WW and Yang BB. MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response. Oncoscience. 2014; 1:531-539.
29. Donzelli S, Strano S and Blandino G. microRNAs: short non-coding bullets of gain of function mutant p53 proteins. Oncoscience. 2014; 1:427-433.
30. Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH, Li YN, Tian YP, Yan L and Wu B. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncology research. 2012; 20:139-147.
31. Yang Z, Han Y, Cheng K, Zhang G and Wang X. miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells. Cell proliferation. 2014; 47:587-595.
32. Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, Tanaka Y, Dahiya R and Yamamura S. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PloS one. 2013; 8:e67686.
33. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Chiyomaru T, Fukuhara S, Tanaka Y, Deng G, Tabatabai ZL and Dahiya R. MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PloS one. 2012; 7:e46743.
34. Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B and Ye Q. miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. FEBS letters. 2014; 588:1913-1920.
35. Yu X, Li Z and Liu J. MiRNAs in primary cutaneous lymphomas. Cell proliferation. 2015; 48:271-277.
36. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, deCarvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T and Brodie C. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013; 4:665-676.
37. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, Bobbitt K, Rempel SA, Hasselbach L, Mikkelsen T, Slavin S and Brodie C. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013; 4:346-361.
38. Liu L, Nie J, Chen L, Dong G, Du X, Wu X, Tang Y and Han W. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PloS one. 2013; 8:e55532.
39. Perfetti A, Greco S, Bugiardini E, Cardani R, Gaia P, Gaetano C, Meola G and Martelli F. Plasma microRNAs as biomarkers for myotonic dystrophy type 1. Neuromuscular disorders: NMD. 2014; 24:509-515.
40. Kolla V, Zhuang T, Higashi M, Naraparaju K and Brodeur GM. Role of CHD5 in human cancers: 10 years later. Cancer research. 2014; 74:652-658.
41. Thompson PM, Gotoh T, Kok M, White PS and Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene. 2003; 22:1002-1011.
42. Li H, Xu W, Huang Y, Huang X, Xu L and Lv Z. Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo. International journal of molecular medicine. 2012; 30:1081-1086.
43. Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y and Gu X. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PloS one. 2012; 7:e29750.
44. Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B and Ma W. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer. 2012; 76:324-331.
45. Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H and Ashktorab H. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer. 2014; 120:172-180.
46. Wang X, Lau KK, So LK and Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. Journal of biomedical science. 2009; 16:95.
47. Wang J, Chen H, Fu S, Xu ZM, Sun KL and Fu WN. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral oncology. 2011; 47:601-608.
48. Zhao R, Wang N, Huang H, Ma W and Yan Q. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma. Liver international: official journal of the International Association for the Study of the Liver. 2014; 34:e151-160.